research Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices
This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.